Hypocretin/orexin disturbances in neurological disorders

Sleep Medicine Reviews

Volumn 13, Issue 1, 2009, Pages 9-22

  Fronczek, Rolf ^a,b   Baumann, Christian Rainer ^c   Lammers, Gert Jan ^b   Bassetti, Claudio Lino ^c   Overeem, Sebastiaan ^d,e  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

Author keywords

Cerebrospinal fluid (CSF); Hypocretin; Narcolepsy; Neurodegenerative disorders; Neuromuscular disorders; Orexin; Radioimmunoassay (RIA); Trauma

Indexed keywords

AUTOANTIBODY; G PROTEIN COUPLED RECEPTOR; HLA DQB1 ANTIGEN; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR;

ALZHEIMER DISEASE; AUTOPSY; BRAIN TISSUE; CATAPLEXY; CEREBROSPINAL FLUID LEVEL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; GENETIC SUSCEPTIBILITY; GUILLAIN BARRE SYNDROME; HLA TYPING; HUMAN; HUNTINGTON CHOREA; HYPERSOMNIA; IDIOPATHIC DISEASE; INTERNATIONAL CLASSIFICATION OF DISEASES; LABORATORY TEST; LATENT PERIOD; MULTIPLE SCLEROSIS; MULTIPLE SLEEP LATENCY TEST; NARCOLEPSY; NERVE CELL; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RADIOIMMUNOASSAY; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SLEEP WAKING CYCLE; TRAUMATIC BRAIN INJURY;

ANIMALS; HUMANS; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVOUS SYSTEM DISEASES; NEURONS; NEUROPEPTIDES; SLEEP DISORDERS;

EID: 58249093837     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smrv.2008.05.002     Document Type: Review

References (79)

1. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000) 991-997
2. Hagan J.J., Leslie R.A., Patel S., Evans M.L., Wattam T.A., Holmes S., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 96 (1999) 10911-10916
3. Nishino S., Ripley B., Overeem S., Lammers G.J., and Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 (2000) 39-40
4. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
5. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
6. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95 (1998) 322-327
7. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
8. Peyron C., Tighe D.K., van Den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18 (1998) 9996-10015
9. Dube M.G., Kalra S.P., and Kalra P.S. Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action. Brain Res 842 (1999) 473-477
10. Yamada H., Okumura T., Motomura W., Kobayashi Y., and Kohgo Y. Inhibition of food intake by central injection of anti-orexin antibody in fasted rats. Biochem Biophys Res Commun 267 (2000) 527-531
11. Yamanaka A., Sakurai T., Katsumoto T., Yanagisawa M., and Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 849 (1999) 248-252
12. Samson W.K., Gosnell B., Chang J.K., Resch Z.T., and Murphy T.C. Cardiovascular regulatory actions of the hypocretins in brain. Brain Res 831 (1999) 248-253
13. Dun N.J., Le D.S., Chen C.T., Hwang L.L., Kwok E.H., and Chang J.K. Orexins: a role in medullary sympathetic outflow. Regul Pept 96 (2000) 65-70
14. Hara J., Beuckmann C.T., Nambu T., Willie J.T., Chemelli R.M., Sinton C.M., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30 (2001) 345-354
15. Nishino S., and Mignot E. Article reviewed: plasma orexin-A is lower in patients with narcolepsy. Sleep Med 3 (2002) 377-378
16. Higuchi S., Usui A., Murasaki M., Matsushita S., Nishioka N., Yoshino A., et al. Plasma orexin-A is lower in patients with narcolepsy. Neurosci Lett 318 (2002) 61-64
17. Dalal M.A., Schuld A., Haack M., Uhr M., Geisler P., Eisensehr I., et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 56 (2001) 1749-1751
18. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59 (2002) 1553-1562
19. Chen C.T., Dun S.L., Kwok E.H., Dun N.J., and Chang J.K. Orexin A-like immunoreactivity in the rat brain. Neurosci Lett 260 (1999) 161-164
20. Ripley B., Overeem S., Fujiki N., Nevsimalova S., Uchino M., Yesavage J., et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 57 (2001) 2253-2258
21. Gerashchenko D., Murillo-Rodriguez E., Lin L., Xu M., Hallett L., Nishino S., et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 184 (2003) 1010-1016
22. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van P.J., van Duinen S.G., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130 (2007) 1577-1585
23. Aziz NA, Fronczek R, Maat-Schieman MLC, Unmehopa UA, Roelandse FW, Overeem S, et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathology, 2008. doi:10.1111/j.1750-3639.2008.00135.x.
24. Crocker A., Espana R.A., Papadopoulou M., Saper C.B., Faraco J., Sakurai T., et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65 (2005) 1184-1188
25. Blouin A.M., Thannickal T.C., Worley P.F., Baraban J.M., Reti I.M., and Siegel J.M. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 65 (2005) 1189-1192
26. Dauvilliers Y., Arnulf I., and Mignot E. Narcolepsy with cataplexy. Lancet 369 (2007) 499-511
27. Lin L., Hungs M., and Mignot E. Narcolepsy and the HLA region. J Neuroimmunol 117 (2001) 9-20
28. American Academy of Sleep Medicine. International classification of sleep disorders. 2nd ed. (2005), American Academy of Sleep Medicine, Rochester, MN
29. Mignot E., Lin L., Finn L., Lopes C., Pluff K., Sundstrom M.L., et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 129 (2006) 1609-1623
30. Ebrahim I.O., Sharief M.K., de Lacy S., Semra Y.K., Howard R.S., Kopelman M.D., et al. Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia. J Neurol Neurosurg Psychiatry 74 (2003) 127-130
31. Allen R.P., Mignot E., Ripley B., Nishino S., and Earley C.J. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 59 (2002) 639-641
32. Stiasny-Kolster K., Mignot E., Ling L., Möller J.C., Cassel W., and Oertel W.H. CSF hypocretin-1 levels in restless legs syndrome. Neurology 61 (2003) 1426-1429
33. Poceta J.S., Parsons L., Engelland S., and Kripke D.F. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med (2008) 10.1016/j.sleep.2007.11.002
34. Arnulf I., Bonnet A.M., Damier P., Bejjani B.P., Seilhean D., Derenne J.P., et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55 (2000) 281-288
35. Hobson D.E., Lang A.E., Martin W.R., Razmy A., Rivest J., and Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 287 (2002) 455-463
36. Overeem S., van Hilten J.J., Ripley B., Mignot E., Nishino S., and Lammers G.J. Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology 58 (2002) 498-499
37. Baumann C., Ferini-Strambi L., Waldvogel D., Werth E., and Bassetti C.L. Parkinsonism with excessive daytime sleepiness - a narcolepsy-like disorder?. J Neurol 252 (2005) 139-145
38. Yasui K., Inoue Y., Kanbayashi T., Nomura T., Kusumi M., and Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 250 (2006) 120-123
39. Drouot X., Moutereau S., Nguyen J.P., Lefaucheur J.P., Creange A., Remy P., et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61 (2003) 540-543
40. Thannickal T.C., Lai Y.Y., and Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130 (2007) 1586-1595
41. Ghorayeb I., Yekhlef F., Chrysostome V., Balestre E., Bioulac B., and Tison F. Sleep disorders and their determinants in multiple system atrophy. J Neurol Neurosurg Psychiatry 72 (2002) 798-800
42. Abdo W.F., Bloem B.R., Kremer H.P., Lammers G.J., Verbeek M.M., and Overeem S. CSF hypocretin-1 levels are normal in multiple-system atrophy. Parkinsonism Relat Disord (2007) 10.1016/j.parkreldis.2007.08.012
43. Martinez-Rodriguez J.E., Seppi K., Cardozo A., Iranzo A., Stampfer-Kountchev M., Wenning G., et al. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. Mov Disord 22 (2007) 1822-1824
44. Benarroch E.E., Schmeichel A.M., Sandroni P., Low P.A., and Parisi J.E. Involvement of hypocretin neurons in multiple system atrophy. Acta Neuropathol 113 (2007) 75-80
45. Baumann C.R., Dauvilliers Y., Mignot E., and Bassetti C.L. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur Neurol 52 (2004) 73-76
46. Aziz N.A., Swaab D.F., Pijl H., and Roos R.A. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 18 (2007) 223-251
47. Petersen A., Gil J., Maat-Schieman M.L., Bjorkqvist M., Tanila H., Araujo I.M., et al. Orexin loss in Huntington's disease. Hum Mol Genet 14 (2005) 39-47
48. Bjorkqvist M., Petersen A., Nielsen J., Ecker D., Mulder H., Hayden M.R., et al. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin Genet 70 (2006) 78-79
49. Baumann C.R., Hersberger M., and Bassetti C.L. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J Neurol 253 (2006) 1232-1233
50. Gaus S.E., Lin L., and Mignot E. CSF hypocretin levels are normal in Huntington's disease patients. Sleep 28 (2005) 1607-1608
51. Meier A., Mollenhauer B., Cohrs S., Rodenbeck A., Jordan W., Meller J., et al. Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease. Brain Res 1063 (2005) 201-203
52. Van Someren E.J. Circadian rhythms and sleep in human aging. Chronobiol Int 17 (2000) 233-243
53. Friedman L.F., Zeitzer J.M., Lin L., Hoff D., Mignot E., Peskind E.R., et al. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 68 (2007) 793-794
54. Ouellet M.C., and Morin C.M. Subjective and objective measures of insomnia in the context of traumatic brain injury: a preliminary study. Sleep Med 7 (2006) 486-497
55. Baumann C.R., Werth E., Stocker R., Ludwig S., and Bassetti C.L. Sleep-wake disturbances 6 months after traumatic brain injury: a prospective study. Brain 130 (2007) 1873-1883
56. Castriotta R.J., Wilde M.C., Lai J.M., Atanasov S., Masel B.E., and Kuna S.T. Prevalence and consequences of sleep disorders in traumatic brain injury. J Clin Sleep Med 3 (2007) 349-356
57. Crompton M.R. Hypothalamic lesions following closed head injury. Brain 94 (1971) 165-172
58. Crompton M.R. Brainstem lesions due to closed head injury. Lancet 1 (1971) 669-673
59. Baumann C.R., Stocker R., Imhof H.G., Trentz O., Hersberger M., Mignot E., et al. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 65 (2005) 147-149
60. Scammell T.E. Secondary narcolepsy. In: Culebras A. (Ed). Sleep disorders and neurologic disease (2007), Informa Healthcare, New York 117-134
61. Guilleminault C., Faull K.F., Miles L., and van den H.J. Posttraumatic excessive daytime sleepiness: a review of 20 patients. Neurology 33 (1983) 1584-1589
62. Guilleminault C., Yuen K.M., Gulevich M.G., Karadeniz D., Leger D., and Philip P. Hypersomnia after head-neck trauma: a medicolegal dilemma. Neurology 54 (2000) 653-659
63. Oka Y., Kanbayashi T., Mezaki T., Iseki K., Matsubayashi J., Murakami G., et al. Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis. J Neurol 251 (2004) 885-886
64. Kato T., Kanbayashi T., Yamamoto K., Nakano T., Shimizu T., Hashimoto T., et al. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med 42 (2003) 743-745
65. Cochen V., Arnulf I., Demeret S., Neulat M.L., Gourlet V., Drouot X., et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barre syndrome. Brain 128 (2005) 2535-2545
66. Nishino S., Kanbayashi T., Fujiki N., Uchino M., Ripley B., Watanabe M., et al. CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 61 (2003) 823-825
67. Overeem S., Geleijns K., Garssen M.P., Jacobs B.C., van Doorn P.A., and Lammers G.J. Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. Neurosci Lett 341 (2003) 13-16
68. Dalmau J., Graus F., Villarejo A., Posner J.B., Blumenthal D., Thiessen B., et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 (2004) 1831-1844
69. Overeem S., Dalmau J., Bataller L., Nishino S., Mignot E., Verschuuren J., et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 62 (2004) 138-140
70. Compta Y., Iranzo A., Santamaria J., Casamitjana R., and Graus F. REM sleep behavior disorder and narcoleptic features in anti-Ma2-associated encephalitis. Sleep 30 (2007) 767-769
71. Laberge L., Begin P., Montplaisir J., and Mathieu J. Sleep complaints in patients with myotonic dystrophy. J Sleep Res 13 (2004) 95-100
72. Gibbs III J.W., Ciafaloni E., and Radtke R.A. Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy. Sleep 25 (2002) 662-665
73. Martinez-Rodriguez J.E., Lin L., Iranzo A., Genis D., Marti M.J., Santamaria J., et al. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 26 (2003) 287-290
74. Ciafaloni E., Mignot E., Sansone V., Hilbert J.E., Lin L., Lin X., et al. The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology 70 (2008) 226-230
75. Chen L., Thakkar M.M., Winston S., Bolortuya Y., Basheer R., and McCarley R.W. REM sleep changes in rats induced by siRNA-mediated orexin knockdown. Eur J Neurosci 24 (2006) 2039-2048
76. Saper C.B., Scammell T.E., and Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 437 (2005) 1257-1263
77. Overeem S., Black III J.L., and Lammers G.J. Narcolepsy: immunological aspects. Sleep Med Rev 12 (2008) 95-107
78. Scammell T.E. The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy. Sleep 29 (2006) 601-602
79. Overeem S., Verschuuren J.J., Fronczek R., Schreurs L., den Hertog H., Hegeman-Kleinn I.M., et al. Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. J Neuroimmunol 174 (2006) 187-191